our work

Late-Breaking Results for Tildrakizumab Phase-3 Studies Presented for First Time

Results from two pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab in patients with moderate-to-severe psoriasis were included as part of the “Breaking News” session at the latest EADV Congress, the premier European dermatology conference where the latest in research and development in the field are presented each year.

Download press release